AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27072546
Drug: Low G
RxNorm normalized name: Yellow Ginger Root
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low G tolerance group (L group)
Trial: 25351474
Drug: MEM 1414
RxNorm normalized name: MEM 1414
DrugBank: MEM 1414 (DB05888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEM 1414 (600 mg, twice daily orally for 7 days)
Trial: 17906853
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) - intravenous bolus of 100 mg preceding a continuous infusion of 10 mg/h (n = 15)
Trial: 16425053
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment in combination with cognitive behavioural therapy
Trial: 1511475
Drug: Fruits and
RxNorm normalized name: Aminobenzoic Acid/Ascorbic Acid/Biotin/Calcium/Cholecalciferol/Choline Bitartrate/Copper/Cyanocobalamin/Folic Acid/Inositol/Iodine/Iron/Magnesium/Manganese/Niacin/Pantothenic Acid/Phosphorus/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin E/Zinc 5 MG-180 MG-300 MCG-120 MG-30 MCG-5 MG-2 MG-18 MCG-800 MCG-5 MG-150 MCG-18 MG-100 MG-2 MG-20 MG-30 MG-15 MG-2 MG-5.1 MG-4.5 MG-2250 MCG-7 MG-5 MG Oral Tablet [MEGAVITE WITH FRUITS AND VEGGIES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruits and vegetables (mean 582 g/day) for 12 weeks
Trial: 29856132
Drug: Psychotropic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic drug intake
Trial: 25063905
Drug: OCP containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCP containing 30 mcg ethinyl estradiol (EE) plus 3 mg drospirenone for 3 months (Group 1)
Trial: 25063905
Drug: OCP containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCP containing 30 mcg ethinyl estradiol (EE) plus 3 mg drospirenone for 3 months (Group 3)
Trial: 25063905
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (Group 2)
Trial: 25063905
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication (Group 4)
Trial: 18372689
Drug: Daily 1
RxNorm normalized name: Beauty 360 Daily 1.2% Moisturizing Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 1 hr short radius centrifugation
Trial: 12011773
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate (300 mg magnesium)
Trial: 9787979
Drug: Leukocyte interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leukocyte interferon-alpha (1 MU three times weekly for one year)
Trial: 9787979
Drug: Leukocyte interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leukocyte interferon-alpha (3 MU three times weekly for a second cycle)
Trial: 7667053
Drug: Dexamethasone (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.6 mg/kg/day iv, divided into 4 daily doses for 4 days)
Trial: 2764271
Drug: Theophylline injection,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline injection, 4 mg/kg body weight
Trial: 18641035
Drug: NRTI-sparing regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRTI-sparing regimen (NNRTI + boosted protease inhibitor)
Trial: 16510640
Drug: Urinary antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary antibiotic prophylaxis
Trial: 16510640
Drug: No urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No urinary antibiotic prophylaxis (Control)
Trial: 15510485
Drug: Topical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mitomycin C (MMC) during trabeculectomy
Trial: 11022835
Drug: Pinaverlum bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverlum bromide (50 mg, t.i.d.)
Trial: 11022835
Drug: Mebeverine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine (100 mg, t.i.d.)
Trial: 9486028
Drug: latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: latanoprost 0.005% once daily for 4 weeks
Trial: 9486028
Drug: latanoprost 0.001%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: latanoprost 0.001% once daily for 4 weeks
Trial: 3551827
Drug: Praziquantel at
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel at a dose of 75 mg/kg per day
Trial: 31526286
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg daily
Trial: 31526286
Drug: PUVA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA (3 weekly sessions)
Trial: 31591018
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone 4 mg
Trial: 31591018
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) dexamethasone 4 mg
Trial: 25066385
Drug: Xylazine administered
RxNorm normalized name: Xylazine
DrugBank: Xylazine (DB11477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine administered intravenously (i.v.)
Trial: 25066385
Drug: Xylazine administered
RxNorm normalized name: Xylazine
DrugBank: Xylazine (DB11477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylazine administered intra-osseously (IO)
Trial: 18343265
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) nasal spray (110 microg)
Trial: 18343265
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) nasal spray (200 microg)
Trial: 27670577
Drug: Short-course antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course antibiotics (4 days)
Trial: 27670577
Drug: Long-course antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course antibiotics (duration not specified)
Trial: 25596054
Drug: Flutamide-combined androgen
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide-combined androgen blockade therapy (F-CAB)
Trial: 25596054
Drug: LH-RH monotherapy
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LH-RH monotherapy
Trial: 22652371
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dl-α-tocopheryl acetate (VE1)
Trial: 22652371
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dl-α-tocopheryl acetate (VE2)
Trial: 22652371
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dl-α-tocopheryl acetate (VE3)
Trial: 20444744
Drug: PRO 2000
RxNorm normalized name: PRO 2000
DrugBank: PRO 2000 (DB05385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO 2000 gel 0.5%
Trial: 20444744
Drug: PRO 2000
RxNorm normalized name: PRO 2000
DrugBank: PRO 2000 (DB05385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO 2000 gel 2%
Trial: 18517084
Drug: Fluticasone furoate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate, 110 microg once daily
Trial: 11872282
Drug: Once-daily thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily thoracic radiation
Trial: 11872282
Drug: Twice-daily thoracic
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily thoracic radiation
Trial: 10442374
Drug: UFT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT plus cisplatin with concurrent radiotherapy
Trial: 2185625
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g glucose
Trial: 2185625
Drug: 0.9 g
RxNorm normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g uncooked cornstarch
Trial: 2185625
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g glucose followed 20 min later by 1.75 g fructose
Trial: 2185625
Drug: 0.9 g
RxNorm normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g uncooked cornstarch followed 20 min later by 1.75 g fructose
Trial: 2185625
Drug: Water followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water followed 20 min later by 1.75 g fructose
Trial: 2185625
Drug: Urinary chromium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary chromium excretion
Trial: 25921600
Drug: Curcumin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (150 mg, theracurmin)
Trial: 14750002
Drug: Sweetened matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweetened matrix formulation of OTFC (200 microg fentanyl)
Trial: 14750002
Drug: Compressed powder
RxNorm normalized name: Ulva compressa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compressed powder formulation of OTFC (200 microg fentanyl)
Trial: 9926788
Drug: Modified laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified laparoscopic intraperitoneal onlay mesh herniorrhaphy (IPOM) using a meshed expanded polytetrafluorethylene (ePTFE) soft tissue patch
Trial: 16756416
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (TN) 42 mg
Trial: 8143465
Drug: Aerosolized ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aerosolized ribavirin (20 mg/mL) for 18 hrs/day for 5 days
Trial: 3065506
Drug: Nisoldipine, 10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine, 10-20 mg daily
Trial: 31606437
Drug: Sofosbuvir plus
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir plus velpatasvir treatment
Trial: 27099485
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg once a day for 3 days, then 250 mg once every 2 days for 3 months)
Trial: 23415640
Drug: Orofacial manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orofacial manual therapy in addition to cervical manual therapy
Trial: 23415640
Drug: Cervical manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical manual therapy (usual care)
Trial: 2548759
Drug: Intracoronary injections
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injections of salbutamol
Trial: 2548759
Drug: Intracoronary injections
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injections of salbutamol after practolol (beta 1-selective blockade)
Trial: 2548759
Drug: Intracoronary injections
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injections of salbutamol after propranolol (beta 1- and beta 2-blockade)
Trial: 2103760
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (500 mg t.d.s.)
Trial: 326491
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg q.d.s.)
Trial: 31090563
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral feeding after MIE
Trial: 25723614
Drug: Standard-dose adalimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose adalimumab (9.48 +/- 5.61 g/mL)
Trial: 25723614
Drug: Low-dose adalimumab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose adalimumab (3.51 +/- 2.21 g/mL)
Trial: 25723614
Drug: Adalimumab dose
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab dose escalation from every other week to weekly
Trial: 23262179
Drug: Low-dose hydrocortisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydrocortisone (0.15mg/kg)
Trial: 23262179
Drug: High-dose hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hydrocortisone (0.45mg/kg)
Trial: 19543144
Drug: Lactobacillus crispatus
RxNorm normalized name: LACTOBACILLUS CRISPATUS
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus crispatus CTV-05 (LACTIN-V) administered by vaginal applicator at doses of 5 x 10, 1 x 10, and 2 x 10 cfu/dose for 5 consecutive days
Trial: 19543144
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by vaginal applicator
Trial: 9815725
Drug: neoadjuvant chemoendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemoendocrine therapy (four 3‐weekly cycles of chemotherapy with mitozantrone, methotrexate (+/‐ mitomycin C), and tamoxifen)
Trial: 9815725
Drug: neoadjuvant chemoendocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemoendocrine therapy
Trial: 30238870
Drug: 10-ml/kg fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-ml/kg fluid bolus
Trial: 30238870
Drug: 20-ml/kg fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-ml/kg fluid bolus
Trial: 24851943
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (TEA) with continuous administration of 0.25% bupivacaine
Trial: 24851943
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia alone with intravenous analgesia (fentanyl: intubation 2 µg/kg; maintenance 0.1‐0.3 mg)
Trial: 12593597
Drug: Naproxen (275
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (275 mg)
Trial: 8450107
Drug: Enhanced Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Behavioral Marital Therapy (EBMT)
Trial: 25008579
Drug: Soy-protein diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy-protein diet (30 g/d soy protein)
Trial: 15709987
Drug: CDP571 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP571 (20 mg/kg at week 0 and 10 mg/kg at week 8)
Trial: 27029918
Drug: Iron-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-enriched yeast (2.5 mg 58Fe)
Trial: 27029918
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (2.5 mg 57Fe)
Trial: 27029918
Drug: Iron-enriched yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-enriched yeast (2.5 mg 58Fe) with bread and butter
Trial: 27029918
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (2.5 mg 57Fe) with bread and butter
Trial: 25836918
Drug: Hydroxytyrosol 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxytyrosol 5 mg/d
Trial: 25836918
Drug: Hydroxytyrosol 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxytyrosol 25 mg/d
Trial: 25836918
Drug: Hydroxytyrosol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxytyrosol (both doses)
Trial: 24050512
Drug: Esomeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d) (EBMT)
Trial: 24050512
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.) (MEA)
Trial: 14697022
Drug: Control (air
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (air treatment)
Trial: 11360072
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (2.5 ml of 0.5% bupivicaine)
Trial: 11360072
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia (15 ml of 0.5% bupivicaine)
Trial: 9125675
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of acetazolamide with diuretic therapy
Trial: 9125675
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with hydrochlorothiazide or furosemide
Trial: 8150549
Drug: Cefpirome 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 1.0 g
Trial: 2878632
Drug: Beta 2-agonist
RxNorm normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 2-agonist terbutaline (5 mg)
Trial: 2878632
Drug: Beta 1
RxNorm normalized name: Beta 1 Kit
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta 1 + 2-agonist orciprenaline (10 mg)
Trial: 2878632
Drug: Beta 1-antagonist
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 1-antagonist acebutolol (200 mg)
Trial: 2878632
Drug: Beta 1-antagonist
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 1-antagonist metoprolol (50 mg)
Trial: 2878632
Drug: Beta 1
RxNorm normalized name: Beta 1 Kit
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta 1 + 2-antagonist propranolol (5 mg)
Trial: 2878632
Drug: Beta 1
RxNorm normalized name: Beta 1 Kit
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta 1 + 2-antagonist with ISA pindolol (5 mg)
Trial: 2878632
Drug: Beta 1-antagonists
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 1-antagonists (acebutolol and metoprolol)
Trial: 27035842
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion 0.5 μg/kg/h throughout the surgery after a loading dose of 1 μg/kg over 10 minutes, continued at 0.2 μg/kg/h for 24 hours postoperatively
Trial: 26154345
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training + protein (whey 17 g + colostrum 3 g + leucine 2 g)
Trial: 8062311
Drug: Uniphyl (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl (once-daily theophylline) in No Time Lapse (NTL) group
Trial: 8062311
Drug: Uniphyl (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl (once-daily theophylline) in Time Lapse (TL) group
Trial: 2661612
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 5, 10, 15, 20 mg
Trial: 29753370
Drug: High-dose irbesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose irbesartan combined with spironolactone (group D)
Trial: 29753370
Drug: Low-dose irbesartan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose irbesartan combined with spironolactone (group C)
Trial: 23536690
Drug: MF59-adjuvanted tetravalent
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted tetravalent influenza vaccine
Trial: 23536690
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of tetravalent influenza vaccine
Trial: 23536690
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MF59-adjuvanted A/H5N1 vaccine
Trial: 22235686
Drug: Qilin Pills,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilin Pills, 6 g tid for 12 weeks
Trial: 22235686
Drug: Wuziyanzong Pills,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuziyanzong Pills, 6 g bid for 12 weeks
Trial: 22235686
Drug: Qilin Pills
RxNorm normalized name: Qilib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qilin Pills
Trial: 22235686
Drug: Wuziyanzong Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuziyanzong Pills
Trial: 17181378
Drug: Subcutaneous PTH(1-84)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous PTH(1-84) 100 microg/day
Trial: 17181378
Drug: Subcutaneous PTH(1-84)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous PTH(1-84) 100 microg/day followed by alendronate 10 mg/day
Trial: 17181378
Drug: PTH(1-84) in
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH(1-84) in combination with alendronate
Trial: 11732460
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration (DTP‐HBV‐Hib)